Patents by Inventor Robert Floc'H

Robert Floc'H has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • CYCLOSPORIN A FORMULATIONS AS NANOPARTICLES
    Publication number: 20020016290
    Abstract: Cyclosporin A formulations are provided as amorphous nanoparticle dispersions for physiologic absorption.. The compositions have high bioavailability and patient acceptability. By providing for concentrates comprising lower alkanols and a polyoxyalkylene surfactant as a stable dispersion of cyclosporin A, upon introducing the stable dispersion into an aqueous medium, the subject formulation is produced comprising amorphous bioavailable cyclosporin nanoparticles.
    Type: Application
    Filed: July 10, 1998
    Publication date: February 7, 2002
    Inventors: ROBERT FLOC'H, CHRISTIAN MERLE
  • Cyclosporin a formulations as nanoparticles
    Patent number: 5827822
    Abstract: Cyclosporin A formulations are provided as amorphous nanoparticle dispersions for physiologic absorption. The compositions have high bioavailability and patient acceptability. By providing for concentrates comprising lower alkanols and a polyoxyalkylene surfactant as a stable dispersion of cyclosporin A, upon introducing the stable dispersion into an aqueous medium, the subject formulation is produced comprising amorphous bioavailable cyclosporin nanoparticles.
    Type: Grant
    Filed: March 25, 1996
    Date of Patent: October 27, 1998
    Assignee: Sangstat Medical Corporation
    Inventors: Robert Floc'h, Christian Merle
  • Medicinal products and pure preparations of melarsomine dihydrochloride, process for obtaining them and intermediate products obtained
    Patent number: 5770733
    Abstract: The medicinal product comprises as active principle a melarsomine hydrochloride preparation having a purity of between 98.5 and 100%. The process for obtaining this preparation is stated essentially as follows:step 1, trichlorotriazine (TCT) is converted to diaminochlorotriazine (DCT) in an ammoniacal medium;step 2, the DCT is converted to melarsen acid hydrochloride (MAH) in the presence of arsanilic acid;step 3, the MAH is reduced to melarsen oxide dihydrate; andstep 4, the melarsen oxide dihydrate is converted to melarsomine dihydrochloride in the presence of cysteamine hydrochloride. In each step, a purified preparation of the corresponding intermediate product, or final product in step 4, is obtained.
    Type: Grant
    Filed: September 5, 1996
    Date of Patent: June 23, 1998
    Assignee: Rhone Merieux
    Inventors: Robert Floc'h, Jean-Pierre Etchegaray, Gerard Wolf, Patrick Lubert, Regine Jackie Anne-Marie Mazars
  • Medicinal products and pure preparations of melarsomine dihydrochloride, process for obtaining them and intermediate products obtained
    Patent number: 5635499
    Abstract: The medicinal product comprises as active principle a melarsomine hydrochloride preparation having a purity of between 98.5 and 100%. The process for obtaining this preparation is stated essentially as follows:step 1, trichlorotriazine (TCT) is converted to diaminochlorotriazine (DCT) in an ammoniacal medium;step 2, the DCT is converted to melarsen acid hydrochloride (MAH) in the presence of arsanilic acid;step 3, the MAH is reduced to melarsen oxide dihydrate; andstep 4, the melarsen oxide dihydrate is converted to melarsomine dihydrochloride in the presence of cysteamine hydrochloride. In each step, a purified preparation of the corresponding intermediate product, or final product in step 4, is obtained.
    Type: Grant
    Filed: June 2, 1995
    Date of Patent: June 3, 1997
    Assignee: Rhone Merieux
    Inventors: Robert Floc'h, Jean-Pierre Etchegaray, Gerard Wolf, Patrick Lubert, Regine J. A. M. Mazars
  • Medicinal products and pure preparations of melarsomine dihydrochloride, process for obtaining them and intermediate products obtained
    Patent number: 5459263
    Abstract: The medicinal product comprises as active principle a melarsomine hydrochloride preparation having a purity of between 98.5 and 100%. The process for obtaining this preparation is stated essentially as follows:step 1, trichlorotriazine (TCT) is converted to diaminochlorotriazine (DCT) in an ammoniacal medium;step 2, the DCT is converted to melarsen acid hydrochloride (MAH) in the presence of arsanilic acid;step 3, the MAH is reduced to melarsen oxide dihydrate; andstep 4, the melarsen oxide dihydrate is converted to melarsomine dihydrochloride in the presence of cysteamine hydrochloride. In each step, a purified preparation of the corresponding intermediate product, or final product in step 4, is obtained.
    Type: Grant
    Filed: December 2, 1992
    Date of Patent: October 17, 1995
    Assignee: Rhone Mereiux
    Inventors: Robert Floc'H, Jean-Pierre Etchegaray, Gerard Wolf, Patrick Lubert, Regine J. A. Mazars